23 Apr 2013, BioSpectrum Bureau , BioSpectrum
Singapore: AstraZeneca and Bind Therapeutics entered into a strategic collaboration to develop and commercialize Accurin, a targeted and programmable cancer nanomedicine from Bind's Medicinal Nanoengineering platform, based on a molecularly targeted kinase inhibitor that is developed and owned by AstraZeneca.
The collaboration is based on emerging data suggesting that nanomedicines like Accurins selectively accumulate in diseased tissues and cells, leading to higher drug concentrations at the site of the tumour and reduced exposure to healthy tissues.
Under the terms of the agreement, the companies will work together to complete Investigational New Drug (IND)-enabling studies of the lead Accurin, identified from a previously-completed feasibility programme. AstraZeneca will then have exclusive development and commercialization rights, while Bind will lead manufacturing during the development phase. Bind could receive upfront and pre-approval milestone payments totaling $69 million, and more than $130 million in regulatory and sales milestones and other payments as well as tiered single to double-digit royalties on future sales.
Ms Susan Galbraith, head, Oncology Innovative Medicines Unit, AstraZeneca, said that, "AstraZeneca believes that targeted therapies which specifically address the underlying mechanisms of disease are the future of personalized cancer treatment. Our oncology teams are actively exploring a range of platforms to deliver targeted therapies, with a strategic focus on unlocking the significant potential of nanoparticles in cancer treatment. We view Bind targeted nanomedicines as a leading technology in this field."
Mr Scott Minick, president and CEO, Bind, said that, "We are excited to grow this collaboration with AstraZeneca, a leading global biopharmaceutical company committed to developing innovative medicines for patients. One year ago, BIND started several feasibility projects with major pharmaceutical companies. Our collaboration with AstraZeneca is the first one completed and had very successful results. Due to the advanced nature of this programme, we now plan to move an Accurin with optimised therapeutic properties quickly into product development."